SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

The Trump-branded meme coin is drawing attention amid a volatile price bounce and widespread criticism over its steep decline. Many traders call it a pump-and-dump or scam, while some speculate on another rally or short squeeze.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is under pressure from a broader semiconductor selloff following Intels weak outlook, with traders debating spillover concerns around PC demand and AI spending ahead of AMDs own earnings report. Some see the drop as excessive given AMDs data-center growth and potential share gains, while others point to its valuation and uncertainty about returns on AI infrastructure spending.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Traders are debating a third-party report and show-floor photo suggesting POET was featured in Foxconns photonics ecosystem, which bulls see as support for the existing FIT collaboration; skeptics say it may only show a demo and want company confirmation, purchase orders, or evidence of production shipments. The discussion is also shaped by the share-price decline and anticipation of an earnings update, with concern about commercialization progress alongside optimism about AI-optics demand.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZenecas quarterly results beat expectations, with management also outlining a cost-savings plan to support its drug pipeline; shares rallied and moved above their 200-day average. Traders highlighted the pipeline and call-option activity as signs of continued optimism.

MaxLinear, Inc. engages in the provision of communications systems-on-chip (SoC) solutions used in broadband, mobile and wireline infrastructure, data center, and industrial and multi-market applications. Its products include cable broadband modems and gateways, wireline connectivity devices, radio frequency transceivers, fiber-optic modules, video set-top boxes and gateways, hybrid analog and digital televisions, direct broadcast satellite outdoor and indoor units, and power management and interface products. The company was founded by Kimihiko Imura, Curtis C. Ling, and Kishore V. Seendripu on September 25, 2003 and is headquartered in Carlsbad, CA.

MaxLinear Inc

MaxLinears strong Q3 results and higher outlook, driven by AI data-center and optical infrastructure demand, are the main focus, but shares are falling despite the report. Traders are split between viewing the pullback as volatility and profit-taking and worrying about cash flow and the challenge of gaining share in the 1.6T market.

Dow, Inc. is a holding company, which engages in the development of innovative solutions. It operates through the following segments: Packaging and Specialty Plastics, Industrial Intermediates and Infrastructure, and Performance Materials and Coatings. The Packaging and Specialty Plastics segment consists of hydrocarbons and energy and packaging and specialty plastics. The Industrial Intermediates and Infrastructure segment covers the industrial solutions and polyurethanes, and construction of chemicals. The Performance Materials and Coatings segment includes coatings and performance monomers, and consumer solutions. The company was founded in 1897 and is headquartered in Midland, MI.

Dow Inc

Dow is drawing attention after a bullish move accompanied by heavy call-option activity, with traders debating whether the flow signals further momentum or a late entry. The optimism also reflects rising plastics prices and a recent earnings beat with a stronger outlook, though some remain cautious about the rallys durability.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs planned move from the NYSE to Nasdaq, which could make it eligible for Nasdaq-100 inclusion, is drawing attention alongside plans to add hybrid SUVs. Traders are reacting to the companys technology-focused positioning and recent strength, though some question whether the listing change alone changes the investment case.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegians Q3 results beat expectations and the company raised its full-year outlook, prompting a strong rally and speculation about short covering. Traders characterize the pullback as profit-taking amid a weak broader market, while debating fuel-cost and geopolitical risks against improving turnaround prospects.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY traders are debating whether the recent market selloff will give way to a relief bounce or extend lower, with widespread concern about Big Tech and AI spending returns alongside uncertainty over Iran, oil, midterms, and major earnings. Dip-buyers point to oversold conditions and possible short-covering, while bears warn that the rebound may be a bull trap.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Papua New Guinea, Australia, Ghana, Suriname, Argentina, Peru, Mexico, Canada, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmonts post-earnings drop is the main focus: traders point to a strong results beat and improved cost guidance, but raise concerns about cash flow, future costs, project spending and a broker downgrade. The community is split between buyers viewing the pullback as a correction and traders warning of further downside amid technical weakness and pressure on gold miners.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Labcorp Holdings (LH) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

LH Stock Hits Record Levels, CHE Stock Surges To Over 52-Week Highs – Here’s What’s Driving Investor Enthusiasm

Equity

Labcorp raised its FY2026 revenue and earnings forecasts following a Q3 beat, while Chemed attracted an analyst upgrade after its VITAS business drove Q3 earnings growth.

Labcorp Hldgs Q3 2026 Earnings Call Transcript

Labcorp Hldgs (NYSE:LH) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.read more...

LH Stock Rises on Q3 Earnings and Revenue Beat, '26 View Up 

Labcorp shares rise as Q3 earnings and revenues beat estimates, both segments deliver growth, margins expand and the company raises its 2026 financial outlook.

Compared to Estimates, Labcorp (LH) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Labcorp Holdings (LH) Q3 Earnings and Revenues Surpass Estimates

Labcorp (LH) delivered earnings and revenue surprises of +2.80% and +1.13%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance

Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 Guidance Labcorp Reports Strong 2026 Third Quarter Results; Raises Full Year 2026 GuidancePR NewswireBURLINGTON, N.C., Oct. 28, 2026 Results from operations for third quarter 2026 versus third quarter 2025:Revenue: $3.81...

Waters & Labcorp Expand Access to FDA-Approved HPV Screening Tests

WAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.

Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026

Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026 Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026PR...

Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential

Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse PotentialPR NewswireBURLINGTON, N.C., Oct. 22...

• Reported GAAP EPS of $4.78 up 14.35% YoY
• Reported revenue of $3.81B up 6.92% YoY
• Labcorp raised full-year 2026 enterprise revenue growth guidance to 5.9% to 6.7% and adjusted EPS guidance to $18.30 to $18.70; free cash flow guidance was $1.24B, unchanged from previous guidance.

Labcorps operating income as a percentage of revenue was 10.6% versus 11.1% in Q3 2025; cash was $261.8M versus $532.3M at December 31, 2025, with competition and technology adaptation listed as risks.

Labcorp reported 6.9% revenue growth and 14.5% adjusted EPS growth, received FDA approval for a melanoma companion diagnostic, and announced or closed four transactions expected to be accretive to adjusted EPS in year one.

Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates through the Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS) segments. The Dx segment includes routine and specialty esoteric testing. The BLS segment consists of central laboratory and ED businesses. The company was founded in 1995 and is headquartered in Burlington, NC.

Labcorp Holdings Inc.

Neutral Sentiment

<ul class="summary-bullets"><li>Labcorp’s Q3 revenue rose 6.9% to $3.81 billion, while adjusted earnings jumped 14.5% to $4.78 per share.</li><li>Leerink raised LH’s price target to $410 from $365, while maintaining an ‘Outperform’ rating, according to The Fly.</li><li>Jefferies upgraded Chemed after it posted a 10.6% increase in Q3 revenue to&nbsp; $690.9 million.</li></ul>Shares of Labcorp (LH) surged to record levels, while Chemed (CHE) shares jumped to over 52-week highs on Wednesday, fueled by stronger-than-expected third-quarter earnings and bullish Wall Street action.<a class="mention" data-mention="$LH" data-symbol-id="LH" href="https://stocktwits.com/symbol/LH" target="_blank">LH shares</a> were up around 10.4% at the time of writing, while <a href="https://stocktwits.com/symbol/CHE">CHE stock</a> gained 9%, reaching its highest level since June 2025.<h2 class="st-heading-2">Labcorp Raises FY2026 Earnings Guidance</h2>Labcorp, which provides medical laboratory testing and diagnostic services, reported a 6.9% increase in third-quarter (Q3) revenue to $3.81 billion, beating Wall Street estimates of $3.76 billion, according to Fiscal.ai. Adjusted earnings per share increased 14.5% to $4.78 from $4.18, exceeding consensus estimates of $4.64.Labcorp expects full-year 2026 revenue growth of 5.9% to 6.7%, raising the midpoint of its previous forecast by 50 basis points.&nbsp;It also increased its adjusted earnings outlook to $18.30 to $18.70 per share, up $0.18 at the midpoint. The company ended the quarter with $261.8 million in cash and $5.85 billion in total debt.Following the results, Leerink raised its price target to $410 from $365 and maintained an ‘Outperform’ rating, according to The Fly. This is an 11.6% upside potential from current levels. Barclays also lifted the stock’s price target to $380 from $330 while retaining an ‘Equal Weight’ rating.Retail sentiment surrounding LH on Stocktwits turned ‘bullish’ from ‘neutral’ over the past 24 hours, amid ‘high’ message volumes. The stock has gained about 46% so far in 2026.<h2 class="st-heading-2">Jefferies Upgrades Chemed After Q3 Earnings Beat</h2>On Wednesday, Jefferies upgraded Chemed to ‘Buy’ from ‘Hold’ and raised its price target to $620 from $520, expecting improving profit margins and steadier earnings growth to support a higher valuation.Chemed, which operates hospice care provider VITAS and plumbing and drain-cleaning business Roto-Rooter, posted a 10.6% increase in Q3 revenue to $690.9 million on Tuesday. This beat Wall Street estimates of $685.8 million. Adjusted earnings per share jumped 28.1% to $6.75, exceeding expectations of $6.44. VITAS revenue increased by 12.2%, while Roto-Rooter sales climbed by 7.5%.BofA also raised the stock’s price target to $555 from $550 but maintained a ‘Neutral’ rating. The firm said VITAS drove the earnings beat, while “Roto side of the business continues to miss.”Retail sentiment surrounding CHE on Stocktwits remained ‘bearish’ over the past 24 hours, amid ‘high’ message volumes. The stock has gained about 30% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/gmab-stock-hits-all-time-high-after-genmab-cancer-drug-trial-meets-primary-goals/cZU9Nu2R9Gh">GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trending stock. (Photo Courtesy of Flavio Coelho via Getty Images)

Chemed Corp.

Laboratory Corp. Of America Holdings

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$361.39
Prev Close	$368.16
Open	$370.00
Dividend Yield	1.15%
50-Day Moving Average	$323.22
Beta	0.52
Avg. Volume	820,241.87
PE Ratio	29.64

52-Week High	$371.00
52-Week Low	$244.52
Market Capitalization	$29.31B
EPS (Annual)	$10.46
Price to Book	3.32
Revenue Per Employee	$196,502.82

Feed

News

Sentiment

Earnings

Fundamentals

Info

LH Fundamentals